利索-全球专利检索

  1. Login
  2. Sign Up
Invention Grant
CN102665422B 通过口服施用重组乳酸乳球菌微型胶囊的免疫保护方法 失效 - 权利终止

  • Patent Title: 通过口服施用重组乳酸乳球菌微型胶囊的免疫保护方法
  • Patent Title (English): Immunoprotection by oral administration of recombinant lactococcus lactis mini-capsules
  • Application No.: CN201080058158.4
    Application Date: 2010-12-23
  • Publication No.: CN102665422B
    Publication Date: 2015-01-28
  • Inventor: 林文傑 , 徐宇虹
  • Applicant: 疫苗基因集团
  • Applicant Address: 中国香港港湾道
  • Assignee: 疫苗基因集团
  • Current Assignee: 疫苗基因集团
  • Current Assignee Address: 中国香港港湾道
  • Agency: 北京天悦专利代理事务所
  • Agent 田明; 任晓航
  • Priority: 61/289,663 2009.12.23 US; PCT/US2010/041792 2010.07.13 US
  • International Application: PCT/US2010/062034 2010.12.23
  • International Announcement: WO2011/079282 EN 2011.06.30
  • Date entered country: 2012-06-20
  • Main IPC: A01N63/00
  • IPC: A01N63/00
通过口服施用重组乳酸乳球菌微型胶囊的免疫保护方法
Abstract:
在一个实施例，本发明以可食用微型胶囊形态提供了一种非持续存在的活重组乳酸乳球菌作为疫苗，用于针对例如高致病性H5N1禽流感病毒等病原体。本发明的肠溶包衣胶囊，在让小鼠和鸡口服后，诱导产生了高浓度的血凝素特异血清免疫球蛋白G和粪便免疫球蛋白A，并当小鼠面对致命剂量的H5N1病毒时，为其提供了完善的保护。因此，本发明示范了一种广泛适用的平台技术，用于生产和施用针对细菌和病毒感染的可食用疫苗。
Abstract(English):

In one embodiment, the present invention provides for an edible mini-capsule form of live, non-persisting, recombinant Lactococcus lactis (L.lactis) vaccine against a pathogen such as the highly virulent influenza H5N1 strain. Enteric coated capsule of the present invention induced high levels of hemagglutinin-specific serum IgG and fecal IgA antibody production after oral administration in mice and chickens, and rendered complete protection against a lethal challenge of H5N1 virus in mice. The present invention thus demonstrates a broadly applicable platform technology for producing and administering edible vaccines against bacterial and viral infections.

Public/Granted literature
Patent Agency Ranking
0/0